Avantel Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AVANTEL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Avantel Limited submitted its unaudited Q1 FY26 results. Standalone revenue from operations came in at ₹5,183.65 lakhs, nearly flat compared to ₹5,165.20 lakhs in Q1 FY25. However, standalone net profit fell sharply to ₹462.40 lakhs from ₹808.19 lakhs a year ago, a drop of about 43%, while profit before tax slipped to ₹669.93 lakhs from ₹1,166.29 lakhs. Consolidated net profit declined to ₹322.71 lakhs from ₹738.07 lakhs, dragged by losses at subsidiary iMeds Global. EPS stood at ₹0.18 (standalone) and ₹0.12 (consolidated) versus ₹0.35 and ₹0.32 respectively last year. The Health Care segment continued to report losses of ₹139.70 lakhs. The company also completed a rights issue of 2.02 crore shares at ₹40 each on May 29, 2025, and included ₹147.40 lakhs of ESOP costs in employee expenses.
Despite stable revenue, sharp profit decline and margin compression are negative for shareholders. The lower earnings are partly due to higher depreciation and ESOP costs following the recent rights issue expansion, but the underlying weakness in profitability, especially in the Health Care segment, may weigh on the stock in the short term.